الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
As global rates for COVID-19 survival have increased, many are wrestling with the long-term sequelae and more interest has grown concerning the prevalence and appropriate management of residual lung disease in survivors of COVID-19.
Post-COVID-19 persistent inflammatory abnormalities on chest radiology have been reported in several cohorts, and observational studies have suggested development of pulmonary fibrosis in a subset of patients.
The aim of the study was to identify the respiratory outcome of patients with COVID-19 pneumonia after three months of recovery.
The study was carried out on 32 patients with COVID-19 pneumonia three months after their recovery recruited from patients with COVID-19 who were diagnosed at Alexandria Main University Hospital with nasopharyngeal swab tested by PCR with positive result.
In the current work, patients’ ages ranged from 22 to 55 years with a mean ± SD of 35.9 ± 9.68 years. Females constituted the majority (62.5%) of patients. The mean BMI was 27.4 ± 4.5 ranging from 21 to 38 kg/m2. (Table 4)
During infection, the assessment of patients showed that 46.87% were isolated in hospital, 31.3% at home and 21.87% needed ICU isolation. Most of patients were CO-RADS 6 (96.9%). Mean of O2 saturation during infection in patients was (81.8 ± 13%) ranged from (53–98%). Eight cases showed normal oxygen saturation, 8 cases were suffering from mild hypoxemia, 8 cases developed moderate hypoxemia and 8 cases suffered severe hypoxemia. (Table 5).
As regards the received treatment during infection, all cases received antibiotic, symptomatic treatment, and supportive treatment, only 7 cases (21.8%) received antiviral therapy were isolated in the ICU. (Table 5)
The most frequent symptoms during infection were fever, cough, fatigue, body ache, and dyspnea grade 4, representing 100%, 93.75%, 81.25%, 71.875%, and 62.5%, respectively. Also, other symptoms were reported including, nausea (31.3%), dyspnea grade 3 (2